Pd0325901 pd901

Manufactured by LC Laboratories

Sourced in United States

PD0325901 (PD901) is a small molecule inhibitor that targets the MEK1 and MEK2 proteins. It functions by inhibiting the kinase activity of these proteins, which are part of the MAPK signaling pathway. PD0325901 is commonly used in research applications to study cellular signaling and proliferation processes.

Automatically generated - may contain errors

Lab products found in correlation

Mln0128, by LC Laboratories (2 mentions) Endotoxin free maxi prep kit, by Merck Group (2 mentions) Maxiprep kit, by Merck Group (1 mentions) Sorafenib, by LC Laboratories (1 mentions) Regorafenib, by LC Laboratories (1 mentions) Selumetinib, by Selleck Chemicals (1 mentions) Pcmv cre, by Addgene (1 mentions) Sch772984, by Selleck Chemicals (1 mentions) U0126, by LC Laboratories (1 mentions)

Spelling variants of this product

PD0325901 (25 citations)

3 protocols using pd0325901 pd901

Plasmid-Mediated Mouse Tumor Modeling

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

pT3-EF1α, pT3-EF1α-HA-myr-AKT, pT3-EF1α-V5-c-MET, and pCMV/sleeping beauty transposase (pCMV/SB) plasmids were described previously [24 (link),42 (link),43 (link)]. An endotoxin-free Maxi Prep Kit (Sigma-Aldrich, St. Louis, MO, USA) was used to purify the plasmids before being injected into mice. Sorafenib, regorafenib, PD0325901 (PD901) and MLN0128 were purchased from LC Laboratories (Woburn, MA, USA).

Liu X., Hu J., Song X., Utpatel K., Zhang Y., Wang P., Lu X., Zhang J., Xu M., Su T., Che L., Wang J., Evert M., Calvisi D.F, & Chen X. (2019). Combined Treatment with MEK and mTOR Inhibitors is Effective in In Vitro and In Vivo Models of Hepatocellular Carcinoma. Cancers, 11(7), 930.

+ Open protocol

+ Expand

Plasmid Construct Mouse Injection

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

The constructs used for mouse injection, including pT3-EF1α, pT3-EF1α-HA-myr-AKT (mouse), pT3-EF1α-YapS127A (human), and pCMV/sleeping beauty transposase (pCMV/SB) plasmids, were described previously^{35 (link)–37 (link)}. Plasmids were purified using the Endotoxin free Maxi Prep Kit (Sigma-Aldrich, St. Louis, MO) before being injected into mice. PD0325901 (PD901) and MLN0128 were purchased from LC Laboratories (Woburn, MA). PD901 and MLN0128 were dissolved in DMSO for in vitro experiments.

Wang P., Song X., Utpatel K., Shang R., Yang Y.M., Xu M., Zhang J., Che L., Gordan J., Cigliano A., Seki E., Evert M., Calvisi D.F., Hu X, & Chen X. (2019). MEK inhibition suppresses K-Ras wild-type cholangiocarcinoma in vitro and in vivo via inhibiting cell proliferation and modulating tumor microenvironment. Cell Death & Disease, 10(2), 120.

+ Open protocol

+ Expand

Genetic Manipulation in Mouse Models

Check if the same lab product or an alternative is used in the 5 most similar protocols

The constructs used for mouse injection, including Myc-tagged pT3-EF1α-NICD and pCMV/sleeping beauty transposase (pCMV/SB) plasmids, were described previously^{21 (link)}. pCMV-Cre was obtained from Addgene (plasmid #11916). Plasmids were purified using the Endotoxin Free Maxi Prep Kit (Sigma-Aldrich, St. Louis, MO) before being injected into the mice. U0126 and PD0325901 (PD901) were purchased from LC Laboratories (Woburn, MA). Selumetinib and SCH772984 were purchased from Selleck Chemicals (Houston, TX).

Dong M., Liu X., Evert K., Utpatel K., Peters M., Zhang S., Xu Z., Che L., Cigliano A., Ribback S., Dombrowski F., Cossu A., Gordan J., Calvisi D.F., Evert M., Liu Y, & Chen X. (2018). Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model. Cell Death & Disease, 9(2), 31.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!